ResMed Inc Net Income
| RMD Stock | USD 275.96 4.33 1.59% |
As of the 10th of February, ResMed holds the Semi Deviation of 1.13, risk adjusted performance of 0.1099, and Coefficient Of Variation of 759.36. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ResMed, as well as the relationship between them. Please check ResMed Inc information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if ResMed Inc is priced some-what accurately, providing market reflects its current price of 275.96 per share. Given that ResMed has jensen alpha of 0.1065, we recommend you to check out ResMed Inc's recent market performance to make sure the company can sustain itself at a future point.
ResMed Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.225 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 1.6 B | 1.7 B | |
| Net Income Applicable To Common Shares | 1.6 B | 1.7 B | |
| Net Income From Continuing Ops | 1.6 B | 1.7 B | |
| Net Income Per Share | 8.59 | 9.02 | |
| Net Income Per E B T | 0.75 | 0.58 |
ResMed | Net Income | Build AI portfolio with ResMed Stock |
Analyzing ResMed's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing ResMed's current valuation and future prospects.
Latest ResMed's Net Income Growth Pattern
Below is the plot of the Net Income of ResMed Inc over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in ResMed Inc financial statement analysis. It represents the amount of money remaining after all of ResMed Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is ResMed's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ResMed's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 1.4 B | 10 Years Trend |
|
Net Income |
| Timeline |
ResMed Net Income Regression Statistics
| Arithmetic Mean | 657,227,322 | |
| Geometric Mean | 386,176,589 | |
| Coefficient Of Variation | 76.54 | |
| Mean Deviation | 406,765,593 | |
| Median | 404,592,000 | |
| Standard Deviation | 503,065,548 | |
| Sample Variance | 253074.9T | |
| Range | 1.7B | |
| R-Value | 0.91 | |
| Mean Square Error | 46414.8T | |
| R-Squared | 0.83 | |
| Slope | 90,653,626 | |
| Total Sum of Squares | 4049199.1T |
ResMed Net Income History
Other Fundumenentals of ResMed Inc
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
ResMed Net Income component correlations
ResMed Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ResMed is extremely important. It helps to project a fair market value of ResMed Stock properly, considering its historical fundamentals such as Net Income. Since ResMed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ResMed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ResMed's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Health Care Equipment & Supplies sector continue expanding? Could ResMed diversify its offerings? Factors like these will boost the valuation of ResMed. Anticipated expansion of ResMed directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ResMed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.145 | Dividend Share 2.26 | Earnings Share 10.1 | Revenue Per Share | Quarterly Revenue Growth 0.11 |
ResMed Inc's market price often diverges from its book value, the accounting figure shown on ResMed's balance sheet. Smart investors calculate ResMed's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since ResMed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between ResMed's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ResMed should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ResMed 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ResMed's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ResMed.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in ResMed on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding ResMed Inc or generate 0.0% return on investment in ResMed over 90 days. ResMed is related to or competes with Alcon AG, IQVIA Holdings, Humana, GE HealthCare, Agilent Technologies, Mettler Toledo, and Becton Dickinson. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for t... More
ResMed Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ResMed's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ResMed Inc upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.36 | |||
| Information Ratio | 0.0617 | |||
| Maximum Drawdown | 5.71 | |||
| Value At Risk | (2.26) | |||
| Potential Upside | 2.13 |
ResMed Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ResMed's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ResMed's standard deviation. In reality, there are many statistical measures that can use ResMed historical prices to predict the future ResMed's volatility.| Risk Adjusted Performance | 0.1099 | |||
| Jensen Alpha | 0.1065 | |||
| Total Risk Alpha | 0.0203 | |||
| Sortino Ratio | 0.0638 | |||
| Treynor Ratio | 0.2255 |
ResMed February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1099 | |||
| Market Risk Adjusted Performance | 0.2355 | |||
| Mean Deviation | 1.06 | |||
| Semi Deviation | 1.13 | |||
| Downside Deviation | 1.36 | |||
| Coefficient Of Variation | 759.36 | |||
| Standard Deviation | 1.41 | |||
| Variance | 1.98 | |||
| Information Ratio | 0.0617 | |||
| Jensen Alpha | 0.1065 | |||
| Total Risk Alpha | 0.0203 | |||
| Sortino Ratio | 0.0638 | |||
| Treynor Ratio | 0.2255 | |||
| Maximum Drawdown | 5.71 | |||
| Value At Risk | (2.26) | |||
| Potential Upside | 2.13 | |||
| Downside Variance | 1.85 | |||
| Semi Variance | 1.28 | |||
| Expected Short fall | (1.12) | |||
| Skewness | 0.1873 | |||
| Kurtosis | 0.7442 |
ResMed Inc Backtested Returns
At this point, ResMed is very steady. ResMed Inc maintains Sharpe Ratio (i.e., Efficiency) of 0.11, which implies the firm had a 0.11 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for ResMed Inc, which you can use to evaluate the volatility of the company. Please check ResMed's Semi Deviation of 1.13, coefficient of variation of 759.36, and Risk Adjusted Performance of 0.1099 to confirm if the risk estimate we provide is consistent with the expected return of 0.16%. ResMed has a performance score of 8 on a scale of 0 to 100. The company holds a Beta of 0.78, which implies possible diversification benefits within a given portfolio. As returns on the market increase, ResMed's returns are expected to increase less than the market. However, during the bear market, the loss of holding ResMed is expected to be smaller as well. ResMed Inc right now holds a risk of 1.45%. Please check ResMed Inc expected short fall, and the relationship between the value at risk and daily balance of power , to decide if ResMed Inc will be following its historical price patterns.
Auto-correlation | -0.03 |
Very weak reverse predictability
ResMed Inc has very weak reverse predictability. Overlapping area represents the amount of predictability between ResMed time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ResMed Inc price movement. The serial correlation of -0.03 indicates that only 3.0% of current ResMed price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.03 | |
| Spearman Rank Test | -0.16 | |
| Residual Average | 0.0 | |
| Price Variance | 63.77 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ResMed Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ResMed Inc reported net income of 1.4 B. This is 310.43% higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 145.32% lower than that of the firm.
ResMed Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ResMed's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ResMed could also be used in its relative valuation, which is a method of valuing ResMed by comparing valuation metrics of similar companies.ResMed is currently under evaluation in net income category among its peers.
ResMed ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ResMed's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ResMed's managers, analysts, and investors.Environmental | Governance | Social |
ResMed Institutional Holders
Institutional Holdings refers to the ownership stake in ResMed that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of ResMed's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ResMed's value.| Shares | Legal & General Group Plc | 2025-06-30 | 971.5 K | Bank Of America Corp | 2025-06-30 | 843.1 K | Goldman Sachs Group Inc | 2025-06-30 | 833.8 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 796.6 K | Nordea Investment Mgmt Bank Demark A/s | 2025-06-30 | 764.2 K | Barclays Plc | 2025-06-30 | 738.9 K | Los Angeles Capital Management Llc | 2025-06-30 | 672.9 K | Squarepoint Ops Llc | 2025-06-30 | 546.4 K | Ubs Group Ag | 2025-06-30 | 533.8 K | Vanguard Group Inc | 2025-06-30 | 18.7 M | Blackrock Inc | 2025-06-30 | 12.4 M |
ResMed Fundamentals
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.28 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 39 B | ||||
| Shares Outstanding | 145.68 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 66.59 % | ||||
| Number Of Shares Shorted | 11.43 M | ||||
| Price To Earning | 73.48 X | ||||
| Price To Book | 6.26 X | ||||
| Price To Sales | 7.34 X | ||||
| Revenue | 5.15 B | ||||
| Gross Profit | 3.32 B | ||||
| EBITDA | 1.91 B | ||||
| Net Income | 1.4 B | ||||
| Cash And Equivalents | 1.21 B | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 851.81 M | ||||
| Debt To Equity | 0.27 % | ||||
| Current Ratio | 2.80 X | ||||
| Book Value Per Share | 43.39 X | ||||
| Cash Flow From Operations | 1.75 B | ||||
| Short Ratio | 12.40 X | ||||
| Earnings Per Share | 10.10 X | ||||
| Price To Earnings To Growth | 1.80 X | ||||
| Target Price | 297.47 | ||||
| Number Of Employees | 10.6 K | ||||
| Beta | 0.88 | ||||
| Market Capitalization | 39.65 B | ||||
| Total Asset | 8.17 B | ||||
| Retained Earnings | 6.08 B | ||||
| Working Capital | 2.49 B | ||||
| Current Asset | 1.42 B | ||||
| Current Liabilities | 637.99 M | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 1.02 % | ||||
| Net Asset | 8.17 B | ||||
| Last Dividend Paid | 2.26 |
About ResMed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ResMed Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ResMed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ResMed Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Will Health Care Equipment & Supplies sector continue expanding? Could ResMed diversify its offerings? Factors like these will boost the valuation of ResMed. Anticipated expansion of ResMed directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ResMed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.145 | Dividend Share 2.26 | Earnings Share 10.1 | Revenue Per Share | Quarterly Revenue Growth 0.11 |
ResMed Inc's market price often diverges from its book value, the accounting figure shown on ResMed's balance sheet. Smart investors calculate ResMed's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since ResMed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between ResMed's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ResMed should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.